PepGen Inc.

BOSTON, MA · Founded 2020 · CIK 0001835597 · Biotech · Public

disease-modifying therapeutics targeting genetic neuromuscular and neurological diseases

pepgen.com →
Grants
—
No SBIR or STTR on record
Sector median 1 award
Raised
$127M
2 Form D · Aug 2021
62 months since last filing
Contracts
—
No federal contracts on record
Patents
14
0 granted · 14 pending
7.0× sector median 2 patents

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history, newest first
DateEventSourceAmount
Private capital raisedForm D · SEC$112,499,887
Private capital raisedForm D · SEC$14,366,712
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3380BlossomHill Therapeutics—$246M
3381Shattuck Labs, Inc.—$164M
3382Colossal Biosciences—$150M
3383PepGen Inc.—$127M
3384MouSensor, Inc.——
3385AGEX THERAPEUTICS INC—$19M
3386Ultragenyx Pharmaceutical Inc.—$109M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Christopher AshtonDirector
  • Ramin Farzaneh-FarDirector
  • Caroline GodfreyDirector · Executive Officer
  • Heidi HensonDirector
  • James McArthurDirector · Executive Officer
  • Josh ResnickDirector
  • Joshua ResnickDirector
  • Matthew WoodDirector

Patents

USPTO · 0 granted of 14
  • Methods Of Treating Duchenne Muscular Dystrophy Using Peptide-oligonucleotide Conjugatesapplication
  • Methods Of Treating Myotonic Dystrophy Type 1 Using Peptide-oligonucleotide Conjugatesapplication
  • Cell-penetrating Peptides, Conjugates Thereof, And Methods Of Their Useapplication
  • Methods And Compositions For Treating Duchenne Muscular Dystrophyapplication
  • Antisense Oligonucleotide Conjugates Targeting Peripheral Myelin Protein 22 (PMP22) And Methods Of Use Thereofapplication
  • Cell-penetrating Peptides, Conjugates Thereof, And Methods Of Their Useapplication
  • Cell-penetrating Peptide Conjugates And Methods Of Their Useapplication
  • Methods Of Treating Duchenne Muscular Dystrophy Using Peptide-ologonucleotide Conjugatesapplication
  • Methods Of Treating Myotonic Dystrophy Type 1 Using Peptide-oligonucleotide Conjugatesapplication
  • Methods Of Treating Duchenne Muscular Dystrophy Using Peptide-oligonucleotide Conjugatesapplication
  • Methods Of Treating Myotonic Dystrophy Type 1 Using Peptide-oligonucleotide Conjugatesapplication
  • Methods And Compositions For Treating Duchenne Muscular Dystrophyapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.